Fotivda: animal efficacy model or human cells?

“In vivo pharmacodynamic studies in mice and rats bearing human or murine xenograft tumors demonstrated that tivozanib inhibited tumor growth at a dose of 0.2 mg/kg in rats, via inhibition of angiogenesis and vascular permeability.”

“Primary pharmacology studies conducted at both molecular and cellular levels and in tumour models have demonstrated that tivozanib hydrochloride is a potent and highly selective inhibitor of the VEGF pathway that exerts strong anti-tumour activities in a broad spectrum of tumour types by blocking tumour angiogenesis.”